VIVO News and Press, Meridian Bioscience Inc. From 04/09/21

Meridian Bioscience benefited from a windfall due to the Covid-19 pandemic, resulting in the growth of its Life Science segment. There will be a market for Covid testing in the post-Covid world, but the eventual market size of Covid testing remains uncertain. Its Diagnostic segmen...

CINCINNATI, April 01, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Compa...

Two new breakout stocks for Week 12 of 2021 with better than 10% short-term upside potential. This past week no selections gained over 10%, but 3 selections peaked at gains of +9%, +8.9%, and +7.9% led by biotechs KDNY and LCTX. 2021 MDA minimal portfolio returns are up +20.3% YTD...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. Focus on XBI. For further details see: Healthcare Dashboard For March And Focus On XBI

The following slide deck was published by Meridian Bioscience, Inc. in conjunction with this event. For further details see: Meridian Bioscience (VIVO) Presents At H.C. Wainwright Global Life Sciences 2021 Virtual Conference - Slideshow

CINCINNATI, March 08, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable Direct DNA qPCR Blood Mix, which is specifically designed for ...

CINCINNATI, March 04, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H.C. Wainwright Global Life Sciences 2021 Virtual Conference. Jack Kenny, Chief Execut...

Meridian Bioscience ([[VIVO]] -8.0%) updates its communication regarding the withdrawal of its application for Emergency Use Authorization ((EUA)) with the U.S. FDA for the SARS-CoV-2 molecular diagnostic test on its Revogene platform.The FDA has now clarified that Meridian will not...

CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (EUA) with the U.S. Food a...

CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided a further update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (F...